The Neurologic Impact of COVID-19: Early Signs, Past Experience

The FDA approved updated dosing for donanemab in early Alzheimer disease, reducing ARIA-E risk by 41% without compromising efficacy.

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

The StateViewer clinical decision support system could help expand access to specialist-level insights in clinics that lack neurology expertise, according to researchers.

The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.